Nevirapine, zidovudine, lamivudine — Competitive Intelligence Brief

Nevirapine, zidovudine, lamivudine (Nevirapine, zidovudine, lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + NRTIs). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + NRTIs) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Nevirapine, zidovudine, lamivudine (Nevirapine, zidovudine, lamivudine) — Institut de Recherche pour le Developpement. This combination of three antiretroviral drugs inhibits HIV reverse transcriptase and non-nucleoside reverse transcriptase to suppress viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nevirapine, zidovudine, lamivudine TARGET	Nevirapine, zidovudine, lamivudine	Institut de Recherche pour le Developpement	phase 3	Antiretroviral combination therapy (NNRTI + NRTIs)	HIV reverse transcriptase
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	Fundacion Clinic per a la Recerca Biomédica	marketed	Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, CYP3A4, HIV reverse transcriptase
Truvada Pill	Truvada Pill	University of North Carolina, Chapel Hill	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
3TC	3TC	Avexa	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; hepatitis B polymerase
Emtricitabine/tenofovir or abacavir/lamivudine	Emtricitabine/tenofovir or abacavir/lamivudine	Fundacion SEIMC-GESIDA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + NRTIs) class)

1. Institut de Recherche pour le Developpement · 1 drug in this class
2. Juan A. Arnaiz · 1 drug in this class
3. University of Cologne · 1 drug in this class